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ABSTRACT 
In this study, a series of novel chromene based 2,6-disubstituted-thiazolo[3,2-b] [1,2,4] triazole derivatives (7a-g) were synthesized by 
condensing 5-substituted-1,2,4-traizole-thione (6a-g) using poly phosphoric acid through one pot reaction. The structure of new compounds 
was supported by 1H NMR, 13C NMR and MS data. The synthesized compounds were evaluated using writhing assays for analgesic and 
carrageenan-induced rat paw edema method for anti-inflammatory activities respectively. Some of the newly synthesized compounds 7c, 7f 
and 7g showed very good anti-inflammatory activity with 90.83%, 85.81% and 88.40% protection respectively along with low GI toxicity as 
compared to standard drug ibuprofen while compounds 7a, 7b, 7d and 7f showed highest analgesic activity with 52.54%, 54.02%, 56.76% and 
52.45% protection among them compound 7d showed better protection than standard drug ibuprofen.  
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INTRODUCTION 
Chromene appeared as an important structural 
pharmacophore in various natural compounds and reported 
having useful medicinal properties such as antitumor [1], 
antivascular [2], antimicrobial [3], antioxidant [4], TNF-α 
inhibitor [5], antifungal [6], anticoagulant, antispasmolytic, 
estrogenic [7], antiviral [8], anti-helminthic, anticancer [9], 
anti-HIV [10], antitubercular [11], anti-inflammatory [12], 
herbicidal, analgesic and anticonvulsant [13] activity. 
Chromene derivatives can be capable of interacting with 
cellular targets which leads to their anti-inflammatory and 
analgesic activity. Inflammation is the initial response of the 
immune system to infection, irritation or foreign substance 
[14]. The chromene pharmacophore has COX-2 selective 
inhibitions in non-steroidal anti-inflammatory drugs 
(NSAIDs) which provide higher potency, efficacy, and 
selectivity [15-16]. The effectiveness of this useful moiety in 
treatment of inflammation and other problems stimulated 
the development of some more potent and important 
compounds. The structure activity relationship studies 
suggested that substitution in the chromene increases the 
ability of the molecule to prevent inflammation [17]. 
Condensed nucleus systems of 1,2,4-triazole and 1,3,4-
thiadiazole (thiazolo-triazoles) found to have diverse 
pharmacological activities including anti-inflammatory, anti-
edema, and analgesic properties [18-22]. Based on the above 
mentioned studies, the present work aims to design a variety 
of ligands using various chromene based 2,6-disubstituted-
thiazolo[3,2-b][1,2,4]triazole derivatives with the hope to get 
better and safer anti-inflammatory and analgesic agents. The 
title compounds were synthesized as per synthetic protocol 
mentioned in scheme 1.  
MATERIALS AND METHODS 
Chemistry 
LR-grade solvents used were obtained from Merck (Mumbai, 
India), CDH (New Delhi, India), and S.D.fine (Mumbai, India). 
Open tube capillary method adopted for determining melting 
point and was uncorrected. Thin layer chromatography 
(TLC) was performed on Silica gel G (Merck) in the solvent 
system, Benzene: Acetone (8:2, v/v) and Toluene: Ethyl 
acetate: Formic acid (5:4:1, v/v/v); UV lamp and iodine 
chamber were used for visualization of TLC spots. 1H NMR 
and 13C NMR were recorded in DMSO-∂6 or CDCl3 on Bruker 
300 MHz instrument using TMS as internal standard. Mass 
spectra presented as m/z, were recorded on LC/MS of 
Perkin-Elmer, LABINDIA and Applied Biosystem model no. 
API 3000.  
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Experimental Protocol 
Synthesis of 7-hydroxy-4-methyl-2H-chromen-2-one (1) 
Mixture of 4gm of powdered resorcinol in 5ml of ethyl aceto 
acetate was prepared in a conical flask and cooled 15 ml of 
conc. H2SO4 were added dropwise into it, keeping in view the 
temperature does not rise above 10°C [20]. After Stirring for 
10 minutes, the mixture was poured into 50 ml ice cold 
water, filtered, washed and dried.  The compound was found 
pure on TLC examination (B: A, 8:2).  
Synthesis of ethyl 2-(4-methyl-2-oxo-4a,8a-dihydro-2H-
chromen-7-yloxy)acetate (2) 
An equimolar mixture of compound 1 (2.0g, 1.12 mmol), 
ethyl acetoacetate (1.86g, 1.12 mmol)  and anhydrous 
potassium carbonate (2.30gm, 1.68 mmol) in dry acetone 
(50ml) was refluxed on a water bath for 12 hrs. The solid 
was filtered and the excess of solvent was removed under 
reduced pressure. The product was filtered, dried and 
recrystallized. The compound was found pure on TLC 
examination (B: A, 8:2). 
Synthesis of 2-(4-methyl-2-oxo-4a,8a-dihydro-2H-chromen-7-
yloxy)acetohydrazide (3) 
A mixture of 2 (0.01 mol), abs. ethanol (50ml) and hydrazine 
hydrate (0.015 mol; 99%) was heated under reflux on water 
bath for 16 hrs. The alcohol was reduced to half of its volume 
and cooled. The product separated 3 was filtered and 
washed with small portions of cold alcohol first and then 
with cold water, repeatedly and dried. The product was 
purified by recrystallization from suitable solvents. The 
compound was found pure on TLC examination (B: A, 9:1 and 
8:2). 
Synthesis of 2-(2-(4-methyl-2-oxo-2H-chromen-7-
yloxy)acetyl)hydrazinecarbothioamide (4) 
To a solution of corresponding hydrazide 3 (0.02 mol) in 50 
ml of ethanol was added a solution of KSCN (0.03 mol) and 3 
ml of HCl with constant stirring. The mixture was evaporated 
to dryness on a steam bath and heated for an additional 1 h 
with another 50 ml of ethanol. The resulting solid mixture 
was treated with distilled water. The crude 
thiosemicarbazides 4 were used as such for next step. 
Synthesis of 7-((5-mercapto-4H-1,2,4-triazol-3-yl)methoxy)-4-
methyl-2H-chromen-2-one (5) 
To a solution of corresponding thiosemicarbazides 4 (0.01 
mol) in 15 ml of ethanol was added a solution of 10.0% 
NaOH (20 ml) and the reaction mixture was refluxed 
immediately for 5-6 h upto reaction was completed. The 
mixture was cooled and acidified with dilute HCl at pH 5-6. 
The resulting solid was filtered, washed with distill water 
and dried. The crude compound was recrystallized from 
ethanol. 
Yield: 72%; m.p. 164-166°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, 
coumarine), 5.16 (s, 2H, O-CH2), 3.0 (s, 1H, C-S-H), 2.42 (d, 
3H, CH3); 13C NMR (75 MHz, CDCl3, δ in ppm): 1158.2, 159.3, 
160.8, 154.3, 160.2, 111.9, 152.27, 104.0, 112.5, 111.0, 125.8, 
111.0, 71.6, 19.4; ESI MS (m/z): 289.1 (M+); Anal. calcd. for 
C13H11N3O3S: C, 53.97; H, 3.83; N, 14.52; O, 16.59; S, 11.08 
%. Found: C, 53.82; H, 3.87; N, 14.55; O, 16.72; S, 11.09 %. 
General procedure for the synthesis of 5-substituted-1,2,4-
traizole-thione derivatives (6a-g) 
To 0.01 mol of 7-((5-mercapto-4H-1,2,4-triazol-3-
yl)methoxy)-4-methyl-2H-chromen-2-one 5, 0.01 mol of 2-
bromo-1-substituted-ethanone were added in the presence 
of 0.015 mol of KOH in absolute ethanol and refluxed for 10 
h. The reaction mixture was cooled and poured onto crushed 
ice. The resulting solids 6 were filtered, dried and 
recrystallized from mixture of ethanol and dimethyl 
formamide (DMF). 
4-methyl-7-((5-(2-oxo-2-phenylethylthio)-4H-1,2,4-triazol-3-
yl)methoxy)-2H-chromen-2-one (6a) 
Yield: 72%; m.p. 196-198°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.56-7.94 (m, 5H, benzene), 6.97-7.73 (m, 3H, 
coumarine), 6.23 (t, 1H, coumarine), 6.39 (s, 2H, O-CH2), 4.97 
(s, 2H, S-CH2), 3.42 (d, 3H, CH3); 13C NMR (75 MHz, CDCl3, δ 
in ppm): 160.2, 159.3, 158.8, 154.2, 152.7, 111.9, 111.0, 
107.43, 135.13, 127.22, 21.4; ESI MS (m/z): 407.1 (M+); Anal. 
calcd. for C21H17N3O4S: C, 61.90; H, 4.21; N, 10.31; O, 15.71; 
S, 7.87%. Found: C 61.82, H 4.31, N 10.25, O, 15.76; S 7.86 %. 
7-((5-(2-(4-(dimethylamino)phenyl)-2-oxoethylthio)-4H-1,2,4-
triazol-3-yl)methoxy)-4-methyl-2H-chromen-2-one (6b) 
Yield: 74%; m.p. 188-190°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 6.87-7.76 (m, 4H, benzene), 6.97-7.73 (m, 3H, 
coumarine), 6.23 (t, 1H, coumarine), 5.16 (s, 2H, O-CH2), 5.45 
(s, 2H, S-CH2), 3.06 (d, 6H, CH3), 2.42 (s, 3H, CH3); 13C NMR 
(75 MHz, CDCl3, δ in ppm): 194.1, 160.8, 160.2, 159.3, 158.8, 
155.5, 154.3, 152.7,129.7, 125.8, 124.9, 112.5, 111.9, 111.7, 
111.0, 104.0,107.43, 38.2, 135.13, 127.22, 71.6, 41.3, 41.3, 
21.4, 19.4; ESI MS (m/z): 450.1 (M+); Anal. calcd. for 
C23H22N4O4S: C, 61.32; H, 4.92; N, 12.44; O, 14.21; S, 7.12 
%. Found: C, 61.40; H, 4.84; N, 12.40; O, 14.28; S, 7.09 %. 
7-((5-(2-(4-methoxyphenyl)-2-oxoethylthio)-4H-1,2,4-triazol-
3-yl)methoxy)-4-methyl-2H-chromen-2-one (6c) 
Yield: 80%; m.p. 204-206°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.10-7.83 (m, 4H, benzene), 6.95-7.73 (m, 3H, 
coumarine), 6.23 (t, 1H, coumarine), 5.16 (s, 2H, O-CH2), 4.92 
(s, 2H, S-CH2), 3.83 (d, 6H, CH3), 2.42 (s, 3H, CH3); 13C NMR 
(75 MHz, CDCl3, δ in ppm): 158.8, 159.3, 160.8, 154.3, 160.2, 
165.0, 111.9, 152.7, 127.7, 104.0, 114.2, 129.8, 111.0, 125.8, 
129.8, 38.2, 194.1, 71.6, 55.8, 19.6; ESI MS (m/z): 437.1 (M+); 
Anal. calcd. for C22H19N3O5S: C, 60.40; H, 4.38; N, 9.61; O, 
18.29; S, 7.33%. Found: C, 60.46; H, 4.34; N, 9.67; O, 18.32; S, 
7.26%. 
4-methyl-7-((5-(2-oxo-2-(1H-pyrrolo[2,3-b]pyridin-2-
yl)ethylthio)-4H-1,2,4-triazol-3-yl)methoxy)-2H-chromen-2-
one (6d) 
Yield: 72%; m.p. 186-188°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.36-8.43 (m, 3H, pyridine), 6.83 (s, 1H, pyrrole), 
6.95-7.73 (m, 4H, coumarine), 5.16 (s, 2H, O-CH2), 5.0 (s, 1H, 
NH , 2-pyrrole), 4.50 (s, 2H, S-CH2), 2.45 (d, 3H, CH3-
coumarine); 13C NMR (75 MHz, CDCl3, δ in ppm): 
158.8,159.3,155.7, 139.1, 109.1, 121.9, 160.8, 154.3, 160.2, 
142.4, 128.3, 111.9, 152.7, 104.0, 115.6, 112.5, 111.0, 125.8, 
35.2, 178.0, 71.6, 19.4; ESI MS (m/z): 447.1 (M+); Anal. calcd. 
for C22H17N5O4S: C, 59.05; H, 3.83; N, 15.65; O, 14.30; S, 
7.17 %. Found: C, 59.11; H, 3.80; N, 15.68; O, 14.20; S, 7.21 %. 
7-((5-(2-(imidazo[1,2-a]pyridin-3-yl)-2-oxoethylthio)-4H-
1,2,4-triazol-3-yl)methoxy)-4-methyl-2H-chromen-2-one (6e) 
Yield: 74%; m.p. 196-198°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.48 (s, 1H, imidazo-pyridine) 6.86-8.48 (m, 4H, 
imidazo-pyridine), 6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, 
coumarine), 5.16 (s, 2H, O-CH2), 4.50 (s, 2H, S-CH2), 2.42 (d, 
3H, CH3-coumarine); 13C NMR (75 MHz, CDCl3, δ in ppm): 
158.8, 152.2, 159.3, 135.9, 109.1, 129.1, 160.8, 154.3, 160.2, 
128.4, 114.2, 111.9, 152.7, 104.0, 114.6, 126.2, 112.5, 111.0, 
125.8, 35.7, 188.0, 71.6, 19.4; ESI MS (m/z): 447.1 (M+); 
Anal. calcd. for C22H17N5O4S: C, 59.05; H, 3.83; N, 15.65; O, 
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14.30; S, 7.17%. Found: C, 59.15; H, 3.77; N, 15.68; O, 14.20; 
S, 7.20 %. 
4-methyl-7-((5-(2-oxo-2-(pyridin-4-yl)ethylthio)-4H-1,2,4-
triazol-3-yl)methoxy)-2H-chromen-2-one(6f) 
Yield: 76%; m.p. 200-202°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.92-8.82 (m, 4H, pyridine), 6.95-7.73 (m, 4H, 
coumarine), 6.23 (t, 1H, coumarine), 5.16 (s, 2H, O-CH2), 4.77 
(s, 2H, S-CH2), 2.42 (d, 3H, CH3-coumarine); 13C NMR (75 
MHz, CDCl3, δ in ppm): 158.8, 159.3, 160.8, 154.3, 160.2, 
150.9, 152.7, 142.3, 104.0, 119.9, 112.5, 111.9, 111.0, 125.8, 
38.2, 194.1, 71.6, 19.4; ESI MS (m/z): 408.1 (M+); Anal. calcd. 
for C20H16N4O4S: C, 58.81; H, 3.95; N, 13.72; O, 15.67; S, 
7.85 %. Found: C, 58.90; H, 3.90; N, 13.75; O, 15.62; S, 7.83 %. 
4-methyl-7-((5-(2-morpholino-2-oxoethylthio)-4H-1,2,4-
triazol-3-yl)methoxy)-2H-chromen-2-one (6g) 
Yield: 80%; m.p. 187-189°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, 
coumarine),  5.16 (s, 2H, O-CH2), 4.29 (s, 2H, S-CH2), 3.65 (d, 
4H, oxazine), 2.42 (d, 3H, CH3-coumarine); 13C NMR (75 
MHz, CDCl3, δ in ppm): 158.8, 159.3, 160.8, 154.3, 160.2, 
150.9, 152.7, 142.3, 104.0, 119.9, 112.5, 111.9, 111.0, 125.8, 
36.7, 168.2, 71.6, 66.2, 160.2, 47.3, 19.4; ESI MS (m/z): 416.1 
(M+); Anal. calcd. for C19H20N4O5S: C, 54.80; H, 4.84; N, 
13.45; O, 19.21; S, 7.70 %. Found: C, 54.86; H, 4.87; N, 13.38; 
O, 19.25; S, 7.64 %. 
General procedure for the synthesis of 4-methyl-7-((6-
substituted-thiazolo[3,2-b][1,2,4]triazol-2-yl)methoxy)-2H-
chromen-2-one (7a-g) 
To 0.01 mol of 4-methyl-7-((5-(2-oxo-2-substituted-
ethylthio)-4H-1,2,4-triazol-3-yl)methoxy)-2H-chromen-2-
one (6a-g) , approx. 5ml of poly phosphoric acid (PPA) were 
added and refluxed at 125°C for 12 h. The reaction mixture 
was cooled and poured onto crushed ice and neutralized by 
adding NaHCO3. The resulting solid (7a-g) was filtered, dried 
and recrystallized from a mixture of ethanol and dimethyl 
formamide (DMF). 
4-methyl-7-((6-phenylthiazolo[3,2-b][1,2,4]triazol-2-
yl)methoxy)-2H-chromen-2-one (7a) 
Yield: 82%; m.p. 184-186°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.96 (s, 1H, thiazole), 7.41-8.27 (m, 5H, benzene), 
6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, coumarine), 5.16 
(s, 2H, O-CH2), 3.42 (d, 3H, CH3); 13C NMR (75 MHz, CDCl3, δ 
in ppm): 147.9, 117.9, 148.3, 126.7, 160.8, 154.3, 160.2, 
130.1, 111.9, 152.7, 104.0, 127.5, 112.5, 111.0, 125.8, 129.2, 
128.7, 72.0, 19.4,  ; ESI MS (m/z): 389.1 (M+); Anal. calcd. for 
C21H15N3O3S: C, 64.77; H, 3.88; N, 10.79; O, 12.33; S, 8.23 
%. Found: C, 64.80; H, 3.82; N, 10.82; O, 12.38; S, 8.18 %. 
7-((6-(4-(dimethylamino)phenyl)thiazolo[3,2-b][1,2,4]triazol-
2-yl)methoxy)-4-methyl-2H-chromen-2-one (7b) 
Yield: 68%; m.p. 178-180°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.41 (s, 1H, thiazole), 6.82-7.61 (m, 4H, benzene), 
6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, coumarine), 5.16 
(s, 2H, O-CH2), 2.42 (s, 2H, S-CH2), 3.06 (d, 6H, CH3); 13C 
NMR (75 MHz, CDCl3, δ in ppm): 147.9, 117.9, 148.3, 126.7, 
160.8, 154.3, 160.2,155.3, 111.9, 111.9, 152.7, 104.0, 127.5, 
112.7, 128.4, 112.5, 111.0, 112.7, 125.8, 72.0, 41.3, 19.4; ESI 
MS (m/z): 432.1 (M+); Anal. calcd. for C23H20N4O3S: C, 
63.87; H, 4.66; N, 12.95; O, 11.10; S, 7.41 %. Found: C, 63.85; 
H, 4.72; N, 12.86; O, 11.13; S, 7.33 %. 
7-((6-(4-methoxyphenyl)thiazolo[3,2-b][1,2,4]triazol-2-
yl)methoxy)-4-methyl-2H-chromen-2-one (7c) 
Yield: 72%; m.p. 189-191°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.96 (s, 1H, thiazole), 7.05-7.55 (m, 4H, benzene), 
6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, coumarine), 5.16 
(s, 2H, O-CH2), 2.43 (s, 2H, S-CH2), 3.83 (s, 3H, CH3); 13C 
NMR (75 MHz, CDCl3, δ in ppm): 147.9, 117.9, 148.3, 126.7, 
160.8, 154.3, 160.6, 122.4, 155.3, 111.9, 152.7, 104.0,114.8, 
128.5, 112.5, 114.8, 111.0, 128.5, 125.8, 72.0, 55.8, 19.4; ESI 
MS (m/z): 419.1 (M+); Anal. calcd. for C22H17N3O4S: C, 
63.00; H, 4.09; N, 10.02; O, 15.26; S, 7.64 %. Found: C, 62.90; 
H, 4.06; N, 10.12; O, 15.30; S, 7.61 %. 
7-((6-(1H-pyrrolo[2,3-b]pyridin-2-yl)thiazolo[3,2-
b][1,2,4]triazol-2-yl)methoxy)-4-methyl-2H-chromen-2-one 
(7d) 
Yield: 75%; m.p. 198-200°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 8.13 (s, 1H, thiazole), 7.36-8.51 (m, 3H, pyridine), 
6.40 (s, 1H, pyrrole), 6.95-7.73 (m, 4H, coumarine), 5.16 (s, 
2H, O-CH2), 5.0 (s, 1H, NH , 2-pyrrole), 2.42 (d, 3H, CH3-
coumarine); 13C NMR (75 MHz, CDCl3, δ in ppm): 147.9, 
120.1, 148.3, 148.6, 143.2, 139.4, 99.3, 119.6, 160.8, 154.3, 
160.2, 128.3, 111.9, 104.0, 115.6, 112.5, 111.0, 125.8, 72.0, 
19.4; ESI MS (m/z): 429.1 (M+); Anal. calcd. for 
C22H15N5O3S: C, 61.53; H, 3.52; N, 16.31; O, 11.18; S, 7.47 
%. Found: C, 61.58; H, 3.56; N, 16.28; O, 11.20; S, 7.39 %. 
7-((6-(imidazo[1,2-a]pyridin-3-yl)thiazolo[3,2-b][1,2,4]triazol-
2-yl)methoxy)-4-methyl-2H-chromen-2-one (7e) 
Yield: 76%; m.p. 180-182°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 8.13 (s, 1H, thiazole), 7.48 (s, 1H, imidazo-pyridine) 
6.86-8.48 (m, 4H, imidazo-pyridine), 6.95-7.73 (m, 3H, 
coumarine), 6.23 (t, 1H, coumarine), 5.16 (s, 2H, O-CH2), 2.42 
(d, 3H, CH3-coumarine); 13C NMR (75 MHz, CDCl3, δ in ppm): 
147.9, 120.1, 145.1, 148.3, 143.2, 127.9, 119.9, 160.8, 154.3, 
160.2, 127.5, 114.2, 111.9, 152.7, 104.0, 114.6, 126.2,112.5, 
111.0, 125.8, 72.0, 19.4; ESI MS (m/z): 429.1 (M+); Anal. 
calcd. for C22H15N5O3S: C, 61.53; H, 3.52; N, 16.31; O, 11.18; 
S, 7.47 %. Found: C, 61.53; H, 3.52; N, 16.31; O, 11.18; S, 7.47 
%. 
4-methyl-7-((6-(pyridin-4-yl)thiazolo[3,2-b][1,2,4]triazol-2-
yl)methoxy)-2H-chromen-2-one (7f) 
Yield: 82%; m.p. 174-176°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 7.96 (s, 1H, thiazole), 7.99-8.75 (m, 4H, pyridine), 
6.95-7.73 (m, 3H, coumarine), 6.23 (t, 1H, coumarine), 5.16 
(s, 2H, O-CH2), 2.42 (d, 3H, CH3-coumarine); 13C NMR (75 
MHz, CDCl3, δ in ppm): 147.9, 122.5, 148.3, 114.2, 160.8, 
154.3, 160.2, 149.8, 140.3, 111.9, 152.7, 104.0, 121.3, ,112.5, 
111.0, 125.8, 72.0, 19.4; ESI MS (m/z): 408.1 (M+); Anal. 
calcd. for C20H14N4O3S: C, 61.53; H, 3.61; N, 14.35; O, 12.29; 
S, 8.21 %. Found: C, 61.60; H, 3.65; N, 14.30; O, 12.31; S, 8.13 
%. 
4-methyl-7-((6-morpholinothiazolo [3,2-b][1,2,4]triazol-2-
yl)methoxy)-2H-chromen-2-one (7g) 
Yield: 70%; m.p. 156-158°C; 1H NMR (300 MHz, DMSO-d6, δ 
in ppm): 6.31 (s, 1H, thiazole), 6.95-7.73 (m, 3H, coumarine), 
6.23 (t, 1H, coumarine), 5.16 (s, 2H, O-CH2), 3.57-3.65 (d, 4H, 
oxazine), 2.42 (d, 3H, CH3-coumarine); 13C NMR (75 MHz, 
CDCl3, δ in ppm): ): 147.9, 118.6, 148.3, 143.0, 160.8, 154.3, 
66.3, 160.2, 48.4, 111.9, 152.7, 104.0,112.5, 111.0, 125.8, 
72.0, 19.4; ESI MS (m/z): 398.1 (M+); Anal. calcd. for 
C19H18N4O4S: C, 57.27; H, 4.55; N, 14.06; O, 16.06; S, 8.05 
%. Found: C, 57.32; H, 4.58; N, 14.02; O, 16.07; S, 8.00 %. 
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Scheme-1: Synthetic protocol of the title compounds (7a-g). 
 
Ar= -C6H5 , -C6H4N(CH3)2 , -C6H4OCH3 , -C7H5N2 , -C7H5N2 , -C5H4N , -NC4H8O 
 
Biological Evaluations 
Wistar rats and albino mice of either sex weighing 180–200 
and 25–30 g, respectively, were used. The animals obtained 
from Animal House Facility, Adarsh Vijendra Institute of 
Pharmaceutical Sciences, Saharanpur (U.P), India and were 
housed in groups of six at room temperature of 25 ±2°C 
under 12 h light/12 h dark cycle with free access to food and 
water ad libitum. The studies were undertaken with prior 
approval from the Institutional Animal Ethics Committee 
(IAEC) registration No. 1487/PO/a/11/CPCSEA and utmost 
care was taken to insure that the animals were treated in the 
most humane and acceptable manner.  
Anti-inflammatory activity 
The synthesized compounds were evaluated for their anti-
inflammatory activity following carrageenan-induced rat 
paw edema method [23]. The rats were randomly divided 
into groups of six. One group was kept as control, and 
received only 0.5% carboxymethyl cellulose (CMC) solution 
and the other groups were treated with test compounds and 
standard drug (Ibuprofen) at a dose level of 20 mg/kg p.o. 
Carrageenan solution (0.1% in sterile 0.9% NaCl solution) in 
a volume of 0.1 ml was injected subcutaneously into the sub-
plantar region of the right hind paw of each rat, 30 min after 
the administration of the test compounds, and standard 
drugs. The paw volume was measured by saline 
displacement shown on screen of digital Plethysmometer 
(Ugo Basile, Italy) at 3 and 4 h after carrageenan injection. 
Thus, the edema volume in control group (Vc) and that of in 
groups treated with test compounds (Vt) was measured and 
the percentage inhibition of edema was calculated using the 
formula: Anti-inflammatory activity (% inhibition) = [(Vc-
Vt)/Vc ] x 100. 
Analgesic activity 
Analgesic activity was carried out by acetic acid-induced 
writhing method [24] in albino mice. A 1% aqueous acetic 
acid solution (i.p. injection; 0.1 ml) was used as writhing-
inducing agent. Mice were kept individually in the test cage, 
before acetic acid injection and habituated for 30 minutes. 
Screening of analgesic activity was performed after i.p. 
administration of test drugs and the reference drug 
(ibuprofen) at the dose of 20 mg/kg. All the compounds 
were injected as CMC suspension (1%). One group was kept 
as control and received 1% CMC. After 20 min of drug 
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administration, 0.10 ml of 1% acetic acid solution was given 
to mice intraperitoneally. The severity of stretching 
movements consisting of arching of the back, elongation of 
body, and extension of hind limbs was recorded for 20 min 
after administration of acetic acid solution. The analgesic 
activity was presented as % protection. % Analgesic activity 
= (n-n’ /n) x 100, where n and n’ are the mean number of 
writhes of control and test groups, respectively.   
RESULTS AND DISCUSSION 
Chemistry 
7-hydroxy-4-methyl-2H-chromen-2-one (1) synthesized 
through Pechman condensation of resorcinol with ethyl 
acetoacetate which on reflux with anhydrous potassium 
carbonate in dry acetone resulted in synthesis of ethyl 2-(4-
methyl-2-oxo-4a,8a-dihydro-2H-chromen-7-yloxy)acetate 
(2). Compounds 2-(2-(4-methyl-2-oxo-2H-chromen-7-
yloxy)acetyl) hydrazine carbothioamide (4) was synthesized 
by reflux using carbon disulfide and  2-(4-methyl-2-oxo-
4a,8a-dihydro-2H-chromen-7-yloxy)acetohydrazide (3) 
which were synthesized by refluxing with hydrazine hydrate 
in absolute alcohol [18]. Compound 7-((5-mercapto-4H-
1,2,4-triazol-3-yl)methoxy)-4-methyl-2H-chromen-2-one 
(5) was synthesized by  cyclization of 2-(2-(4-methyl-2-oxo-
2H-chromen-7-yloxy)acetyl)hydrazinecarbothioamide (4) in 
presence of ethanol and NaOH. A series of novel 5-
substituted-1,2,4-traizole-thione derivatives (6a-g) were 
synthesized by refluxing 7-((5-mercapto-4H-1,2,4-triazol-3-
yl)methoxy)-4-methyl-2H-chromen-2-one (5) with different 
substituted bromoethanone using potassium hydroxide in 
ethanol. Further, a series of title compounds (7a-g) were 
synthesized by refluxing 5-substituted-1,2,4-traizole-thione 
derivatives (6a-g) with PPA followed by neutralization by 
NaHCO3.  1H NMR, 13C NMR and mass spectra were used for 
the structural characterization of the prepared compounds. 
Anti-inflammatory activity 
Fourteen compounds of the Scheme I were tested for their 
anti-inflammatory activity (Table 1). The compounds 
showed anti-inflammatory activity ranging from 47.67% to 
90.83% inhibition at 4 hr of carrageenan injection, which 
was compared to standard drug ibuprofen (93.57%). Among 
the screened compounds only three compounds 7c, 7f and 
7g showed highest anti-inflammatory activity with 90.83%, 
85.81% and 88.40% protection respectively. Rests of the 
compounds were moderate in their action. 
 
Table 1:- Anti-inflammatory activity (Percent inhibition of edema) 
Compd. no. Body Wt. 
(gm) 
SEM 
Initial Paw 
Vol. 
SEM 
Paw Volume After 
SEM 
Difference After 
SEM 
% Inhibition  
SEM After  
3 hr 4 hr 3 hr 4 hr 3 hr 4 hr 
Control 
150.00 
±2.23 
1.58 
±0.04 
2.37 
±0.03 
2.37 
±0.03 
0.71 
±0.03 
0.77 
±0.03 
  
Ibuprofen 
150.00 
±1.82 
1.70 
±0.06 
1.87 
±0.01 
1.82 
±0.02 
0.12 
±0.02 
0.05 
±0.02 
82.27 
 3.23 
93.57 
2.72 
6a 148.33 
±1.05 
1.45 
±0.02 
1.98 
±0.02 
1.88 
±0.02 
0.49 
±0.03 
0.40 
±0.02 
29.63 
±2.05 
47.67 
±3.66 
6b 145.00 
±1.82 
1.43 
±0.03 
1.83 
±0.07 
1.73 
±0.06 
0.39 
±0.05 
0.30 
±0.04 
48.50 
±5.25** 
60.40 
±4.77 
6c 150.00 
±1.29 
1.37 
±0.03 
1.80 
±0.02 
1.72 
±0.03 
0.43 
±0.02 
0.34 
±0.06 
39.32 
±3.07 
56.24 
±4.17 
6d 146.66 
±1.66 
1.47 
±0.02 
1.82 
±0.03 
1.72 
±0.03 
0.34 
±0.02 
0.25 
±0.01 
50.93 
±4.14 
66.74 
±3.13 
6e 146.66 
±1.66 
1.41 
±0.02 
1.80 
±0.01 
1.68 
±0.01 
0.37 
±0.02 
0.26 
±0.03 
46.17 
±3.90** 
66.13 
±4.03 
6f 147.50 
±1.11 
1.42 
±0.02 
1.88 
±0.02 
1.83 
±0.01 
0.45 
±0.00 
0.40 
±0.02 
35.26 
±2.12 
53.34 
±3.20 
6g 145.00 
±2.23 
1.3 
±0.06 
1.71± 
0.05 
1.64± 
0.05 
0.35± 
0.05 
0.27 
±0.05 
49.97 
±4.29** 
63.89 
±4.14 
7a 160.50 
±2.35 
1.43 
±0.03 
1.78 
±0.04 
1.62 
±0.03 
0.31 
±0.02 
0.24 
±0.01 
42.41 
±2.97 
68.08 
±3.28 
7b 162.50 
±1.70 
1.53 
±0.03 
1.75 
±0.02 
1.68 
±0.04 
0.22 
±0.01 
0.11 
±0.04 
69.71 
±2.15 
81.27 
±3.11 
7c 145.83 
±1.53 
1.53 
±0.03 
1.69 
±0.02 
1.59 
±0.02 
0.14 
±0.02 
0.07 
±0.02 
80.44 
±3.17 
90.83 
±5.02 
7d 153.33 
±1.66 
1.38 
±0.04 
1.78 
±0.04 
1.76 
±0.04 
0.40 
±0.02 
0.37 
±0.01 
43.74 
±1.29* 
50.74 
±1.82 
7e 158.33 
±1.10 
1.53 
±0.01 
2.04 
±0.02 
1.94 
±0.03 
0.51 
±0.01 
0.41 
±0.02 
31.93 
±4.16 
47.08 
±4.46 
7f 148.33 
±1.66 
1.48 
±0.02 
1.67 
±0.02 
1.61 
±0.01 
0.15 
±0.01 
0.11 
±0.06 
78.74 
±1.29* 
85.81 
±5.13 
7g 150.00 
±1.82 
1.59 
±0.01 
1.89 
±0.01 
1.71 
±0.01 
0.29 
±0.02 
0.10 
±0.03 
60.23 
±6.92 
88.40 
±5.73 
Each value represents the mean ± SEM (n = 6), n = number of mice 
Dose = 20 mg/kg; *p < 0.05, **p < 0.01, ***p < 0.001 (compared to standard). 
Data was analyzed by ANOVA’s bonferron’s multiple tests. 
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Analgesic activity 
All fourteen compounds of the Scheme I showed analgesic 
activity (Table 2) ranging from 26.90% to 56.76% 
protection, which was compared to that of standard drug 
ibuprofen (56.20%). Among the screened compounds only 
four compounds 7a, 7b, 7d and 7f showed highest analgesic 
activity with 52.54%, 54.02%, 56.76% and 52.45% 
protection. Compound 7d showed better protection than 
standard drug ibuprofen. Four compounds, 6c, 7c, 7e and 7g 
showed good activity with 47.80, 47.25, 41.89 and 49.05% 
inhibition respectively. Rests of the compounds were 
moderate in their action. 
 
Table 2:- Analgesic activity 
Compd. no. Body wt. (gm) 
±SEM 
No. of writhing 
(15 min)±SEM 
(%) Protection 
±SEM 
Control 26.66±1.05 48.33±0.21 0.00±0.00 
Ibuprofen 25.83±1.53 21.16±0.30 56.20±0.59 
6a 25.83±0.83 35.33±0.61 26.90±1.11 
6b 26.66±1.05 30.66±0.61 36.21±1.25 
6c 31.33±0.33 25.17±0.50 47.80±0.11** 
6d 28.33±1.05 30.16±0.30 37.58±0.73 
6e 26.33±1.05 31.50±0.34 35.51±0.80 
6f 27.50±1.11 28.83±0.30 40.33±0.76* 
6g 28.33±1.05 32.00±0.36 33.79±0.68 
7a 26.66±1.66 23.66±0.33 52.54±0.78** 
7b 27.55±0.89 22.78±0.12 54.02±0.14*** 
7c 31.02±1.12 25±0.40 47.25±0.80* 
7d 26.66±1.66 21.66±0.42 56.76±0.72*** 
7e 28.87±0.84 28.09±0.68 41.89±0.67* 
7f 27.50±1.11 22.98±0.30 52.45±0.38** 
7g 26.66±1.66 24.62±0.23 49.05±0.60* 
Each value represents the mean ± SEM (n = 6), n = number of mice 
Dose = 20 mg/kg; *p < 0.05, **p < 0.01, ***p < 0.001 (compared to standard). 
Data was analyzed by ANOVA’s bonferron’s multiple tests. 
 
CONCLUSION 
Novel chromen based hybrids of thiazolo[3,2-b] 
[1,2,4]triazole were designed, synthesized and characterized 
by different spectroscopic techniques. The prepared 
compounds retain good-to-moderate anti-inflammatory and 
analgesic activity. The methoxy group containg compound 
7c was found to have most prominent anti-inflammatory 
agent while pyrrolo-pyridine containing compound 7d was 
the most potent analgesic agent even showed better 
protection than standard drug ibuprofen. Furthermore, 
molecular docking studies may be carried out to identify 
their possible binding mode within the catalytic domain of 
TNF-α, Cox-1 and Cox-2. 
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